

**This is an electronic reprint of the original article.  
This reprint *may differ* from the original in pagination and typographic detail.**

**Author(s):** Pekkala, Satu; Wiklund, Petri; Hulmi, Juha; Ahtiainen, Juha; Horttanainen, Mia; Laakkonen, Eija; Mäkelä, Kari; Kainulainen, Heikki; Häkkinen, Keijo; Nyman, Kai; Alén, Markku; Herzig, Karl-Heinz; Cheng, Sulin

**Title:** Are skeletal muscle FNDC5 expression and irisin release regulated by exercise and related to health?

**Year:** 2013

**Version:**

**Please cite the original version:**

Pekkala, S., Wiklund, P., Hulmi, J., Ahtiainen, J., Horttanainen, M., Laakkonen, E., Mäkelä, K., Kainulainen, H., Häkkinen, K., Nyman, K., Alén, M., Herzig, K.-H., & Cheng, S. (2013). Are skeletal muscle FNDC5 expression and irisin release regulated by exercise and related to health?. *Journal of Physiology*, 591(21), 5393-5400.  
<https://doi.org/10.1113/jphysiol.2013.263707>

All material supplied via JYX is protected by copyright and other intellectual property rights, and duplication or sale of all or part of any of the repository collections is not permitted, except that material may be duplicated by you for your research use or educational purposes in electronic or print form. You must obtain permission for any other use. Electronic or print copies may not be offered, whether for sale or otherwise to anyone who is not an authorised user.

## RAPID REPORT

## Are skeletal muscle *FNDC5* gene expression and irisin release regulated by exercise and related to health?

Satu Pekkala<sup>1</sup>, Petri K. Wiklund<sup>1</sup>, Juha J. Hulmi<sup>2</sup>, Juha P. Ahtiainen<sup>2</sup>, Mia Horttanainen<sup>1</sup>, Eija Pöllänen<sup>1</sup>, Kari A. Mäkelä<sup>3</sup>, Heikki Kainulainen<sup>2</sup>, Keijo Häkkinen<sup>2</sup>, Kai Nyman<sup>4</sup>, Markku Alén<sup>5</sup>, Karl-Heinz Herzig<sup>3,6</sup> and Sulin Cheng<sup>1</sup>

<sup>1</sup>Department of Health Sciences and <sup>2</sup>Department of Biology of Physical Activity, University of Jyväskylä, Jyväskylä, Finland

<sup>3</sup>Institute of Biomedicine, Division of Physiology and Biocenter of Oulu, University of Oulu, Oulu, Finland

<sup>4</sup>Jyväskylä Central Hospital, Jyväskylä, Finland

<sup>5</sup>Department of Medical Rehabilitation, Oulu University Hospital and Institute of Health Sciences, University of Oulu, Oulu, Finland

<sup>6</sup>Department of Psychiatry, Kuopio University Hospital, Kuopio, Finland

### Key points

- Contradictory findings have been reported concerning the function of irisin and its precursor gene, skeletal muscle *FNDC5*, in energy homeostasis and metabolic health, and the associated regulatory role of exercise and *PGC-1 $\alpha$* .
- We analysed the effects of different short- and long-term exercise regimens on muscle *FNDC5* and *PGC-1 $\alpha$* , and serum irisin, and studied the associations of irisin and *FNDC5* with health parameters.
- *FNDC5* and serum irisin did not change after acute aerobic, long-term endurance training or endurance training combined with resistance exercise (RE) training, or associate with metabolic disturbances. A single RE bout increased *FNDC5* mRNA in young, but not older men (27 vs. 62 years). Changes in *PGC-1 $\alpha$*  or serum irisin were not consistently accompanied by changes in *FNDC5*.
- Our data suggest that the effects of exercise on *FNDC5* and irisin are not consistent, and that their role in health is questionable. Moreover, the regulatory mechanisms should be studied further.

**Abstract** Recently, contradictory findings have been reported concerning the function of irisin and its precursor gene, skeletal muscle *FNDC5*, in energy homeostasis, and the associated regulatory role of exercise and *PGC-1 $\alpha$* . We therefore evaluated whether muscle *FNDC5* mRNA and serum irisin are exercise responsive and whether *PGC-1 $\alpha$*  expression is associated with *FNDC5* expression. The male subjects in the study performed single exercises: (1) 1 h low-intensity aerobic exercise (AE) (middle-aged,  $n = 17$ ), (2) a heavy-intensity resistance exercise (RE) bout (young  $n = 10$ , older  $n = 11$ ) (27 vs. 62 years), (3) long-term 21 weeks endurance exercise (EE) training alone (twice a week, middle-aged,  $n = 9$ ), or (4) combined EE and RE training (both twice a week, middle-aged,  $n = 9$ ). Skeletal muscle mRNA expression was analysed by quantitative PCR and serum irisin by ELISA. No significant changes were observed in skeletal muscle *PGC-1 $\alpha$* , *FNDC5* and serum irisin after AE, EE training or combined EE + RE training. However, a single RE bout increased *PGC-1 $\alpha$*  by 4-fold in young and by 2-fold in older men, while *FNDC5* mRNA only increased in young men post-RE, by 1.4-fold. Changes in *PGC-1 $\alpha$*  or serum irisin were

not consistently accompanied by changes in *FNDC5*. In conclusion, for the most part, neither longer-term nor single exercise markedly increases skeletal muscle *FNDC5* expression or serum irisin. Therefore their changes in response to exercise are probably random and not consistent excluding the confirmation of any definitive link between exercise and *FNDC5* expression and irisin release in humans. Moreover, irisin and *FNDC5* were not associated with glucose tolerance and being overweight, or with metabolic disturbances, respectively. Finally, factor(s) other than *PGC-1 $\alpha$*  and transcription may regulate *FNDC5* expression.

(Resubmitted 13 August 2013; accepted 1 September 2013; first published online 2 September 2013)

**Corresponding author** S. Pekkala: Department of Health Sciences, University of Jyväskylä, PO Box 35, FI-40014 University of Jyväskylä, Finland. Email: satu.p.pekkala@jyu.fi

**Abbreviations** AE, aerobic exercise; EE, endurance exercise; *FNDC5*, fibronectin type III domain containing 5; HOMA-IR, homeostasis model assessment of insulin resistance; *PGC-1 $\alpha$* , peroxisome proliferator-activated receptor- $\gamma$  coactivator; RE, resistance exercise; RM, repetition maximum.

## Introduction

Skeletal muscle is increasingly being recognized as an endocrine organ that releases a variety of signalling molecules called myokines, which regulate several physiological processes. Recently, Boström *et al.* (2012) showed that a novel myokine, irisin (named after the Greek goddess Iris), a proteolytic derivative of the muscle integral membrane protein fibronectin type III domain containing 5 (*FNDC5*), is released into the bloodstream after endurance training in mice and humans. According to their study, irisin is up-regulated by exercise-responsive peroxisome proliferator-activated receptor- $\gamma$  coactivator-1 $\alpha$  (*PGC-1 $\alpha$* ) to activate thermogenic programmes in white adipose tissue suggesting that it could be therapeutic for obesity and type 2 diabetes. Since then it has been questioned whether *FNDC5* and irisin are generally linked to physical exercise and what irisin's role is in metabolic homeostasis (Sharma *et al.* 2012; Timmons *et al.* 2012; Roberts *et al.* 2013).

Timmons *et al.* (2012) showed that muscle *FNDC5* mRNA expression is increased only in a minority of (older) endurance-trained subjects and that exercise-induced improvements in insulin sensitivity are not associated with *FNDC5* gene expression (Timmons *et al.* 2012). Subsequently, it has been demonstrated that skeletal muscle *FNDC5* mRNA and irisin are actually elevated in obese rats without improvement in insulin sensitivity (Sharma *et al.* 2012; Roberts *et al.* 2013). Huh *et al.* (2012) reported that skeletal muscle *FNDC5* mRNA and serum irisin decreased after a surgically induced weight loss and thus were not directly involved with beneficial effects to health (Huh *et al.* 2012). However, the latter study detected slightly increased serum irisin levels in young subjects after acute (but not chronic) sprint exercise (Huh *et al.* 2012). Yet, the latest reports showed that skeletal muscle *FNDC5* expression and circulating irisin levels were decreased in obese patients and associated with insulin sensitivity, and that adipose tissue might secrete irisin in response to exercise (Moreno-Navarrete

*et al.* 2013; Roca-Rivada *et al.* 2013). Altogether, these contradictory results question whether *FNDC5* and irisin link physical activity to energy metabolic homeostasis or whether the effects of exercise on this signalling system are age dependent and/or exercise-type and -duration specific rather than general.

## Methods

### Ethical approval

The samples used in this study are derived from earlier studies that were all approved by the local Ethics Committee of the University of Jyväskylä, Finland and conducted in accordance with the *Declaration of Helsinki*. A written informed consent was obtained from all the subjects.

### Study subjects and exercise protocols

All study subjects were previously untrained healthy men except those used in the microarray data analysis (see below). The following four exercise protocols are included in this report.

(1) An acute low-intensity aerobic exercise (AE) was performed with bicycle ergometry for 1 h at a low intensity of 50% maximum rate of O<sub>2</sub> uptake ( $\dot{V}_{O_{2,max}}$ ) in middle-aged men ( $n = 17$ , age  $53 \pm 4$  years, weight  $84 \pm 12$  kg and body mass index (BMI)  $27 \pm 4$ ; means  $\pm$  SD; unpublished study design).

(2) A single resistance exercise (RE) bout in young ( $n = 10$ , age  $27 \pm 3$  years, weight  $74 \pm 9$  kg and BMI  $23 \pm 2$ ) and older ( $n = 11$ , age  $62 \pm 5$  years, weight  $80 \pm 5$  kg and BMI  $25 \pm 2$ ) men of 5 sets of 10 repetitions in leg press until failure. The RE bout study protocols are described in Hulmi *et al.* (2008, 2009a).

(3) Heavy-intensity endurance exercise (EE;  $n = 9$ , age  $57 \pm 7$  years, weight  $73 \pm 7$  kg and BMI  $24 \pm 2$ ) twice a week and combined EE and RE training ( $n = 9$ , age  $62 \pm 5$  years, weight  $79 \pm 13$  kg and BMI  $25 \pm 3$ ) 2 + 2 times per week for 21 weeks in middle-aged men. The

study protocols for EE and combined EE and RE training are described in Ahtiainen *et al.* (2009). Briefly, the intensity of endurance training was progressively increased and based on the aerobic and anaerobic thresholds. The training was carried out on a bicycle ergometer and heart rate monitoring was used to control the intensity of the exercise. During the first 7 week training period, the subjects trained for 30 min per session under the level of their aerobic threshold. Moreover, a few sessions included cycling above the aerobic threshold in order to become accustomed to a higher intensity. During the second 7 week training period a 45 min session once a week was divided into four loading intervals: 15 min under the level of aerobic threshold, 10 min between the aerobic–anaerobic thresholds, 5 min above the anaerobic threshold, and 15 min again under the aerobic threshold. The other of the two weekly training sessions was 60 min under the aerobic threshold. The focus of training during the third 7 week period was to improve cycling speed and maximal endurance in a 60 min session: 30 min under the aerobic threshold during the whole session altogether, 2 × 10 min between the aerobic–anaerobic thresholds, and 2 × 5 min above the anaerobic threshold. Every other training session included 90 min of cycling at a steady pace under the aerobic threshold. The strength training in the combined EE and RE included leg press, knee extension, bench press, triceps pushdown, lateral pull-down, sit-up and elbow flexion). The 21 week training period consisted of three specific training periods of 7 weeks in duration. Both overall intensity and volume of training increased progressively throughout the training period following the units of a training programme. The total training sessions averaged from 60 to 90 min in length including warming up and cooling down.

(4) The study subjects that performed a heavy-exercise bout (5 × 10 repetitions of bilateral knee extensions with a load of 10 repetition maximum (10 RM)) were early-middle-aged men ( $n = 14$ , age  $34 \pm 7$  years, weight  $85 \pm 8$  kg and BMI  $26 \pm 2$ ).

The study subjects (Table 1) used to analyse the microarray data were derived from a larger study which was aimed at investigating body composition and its determinants ('Investigation of the role of adiposity-related low-grade inflammation on interactions between adipose tissue, muscle, and bone, the AMB-study' supported by the Academy of Finland SKID-KID program 2010–2013). The study was conducted at the University of Jyväskylä in 2008–2010 in accordance with the *Declaration of Helsinki* and was approved by the ethical committee of the Central Finland Health Care district.

### Adipose tissue biopsies and microarray analysis

Altogether 35 subjects provided tissue samples that were taken after an overnight fast between 7 and

9 am under local anaesthesia (lidocaine) after skin cooling and disinfection. A needle biopsy (14 G needle, 2.1 mm × 60 mm) of subcutaneous abdominal adipose tissue was taken at the level of the navel. The samples were cleaned of any visible connective tissue and blood. Biopsies were frozen in liquid nitrogen after withdrawing from the needle and stored at  $-80^{\circ}\text{C}$  until used for RNA isolation. Total RNA from the adipose tissue biopsies was extracted with an optimized protocol using FastPrep systems (MP Biomedicals, France) and RNeasy Lipid Tissue Mini Kit (Qiagen, Germantown, MD, USA).

The quality of the isolated total RNA was studied using the 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) and the Experion Automated Electrophoresis Station (BioRad, Hercules, CA, USA). For the microarray analysis, the total RNA was amplified and processed using the GeneChip 3'IVT Express Kit (Affymetrix, Santa Clara, CA, USA) and hybridized on Affymetrix Human Genome U219 Array Plates. Affymetrix GeneChip Command Console (AGCC) 3.1 was used to control the GeneTitan hybridization process and in summarizing probe cell intensity data. After-hybridization quality was checked with AGCC and Affymetrix Expression Console 1.1.

The gene values of the expression measurements were analysed by using the Robust Multiarray Averaging (RMA) algorithm, as implemented in R package *affy* from Bioconductor. The differentially expressed genes were detected with the *Limma* R package utilizing linear modelling and empirical Bayes methods. Raw *P* values were adjusted using the Benjamini and Hochberg multiple adjustment method. Genes with an adjusted *P* value below 0.05 were considered to be differentially expressed.

### Skeletal muscle biopsies, RNA extraction and RT-PCR

Vastus lateralis biopsies were taken under the effect of lidocaine before and at 3 h post-exercise (except for single RE bout groups for which the sample collection times were before, at 1 h and at 48 h). Total RNA was extracted using Trizol-reagent (Invitrogen, Carlsbad, CA, USA) and a FastPrep Instrument (Bio101 Systems, USA). Three micrograms of total RNA was reverse transcribed according to the manufacturer's instructions using a High Capacity cDNA Synthesis Kit (Applied Biosystems, Foster City, CA, USA).

### Quantitative PCR

*FNDC5* mRNA was quantified using TaqMan primers and probes (Assay ID Hs00401006\_m1) and ABI 7300 Real-Time quantitative PCR System (Applied Biosystems). *PGC-1 $\alpha$*  and the glyceraldehyde 3-phosphate dehydrogenase gene (*GAPDH*) were quantified using in-house-designed primers, iQ SYBR Supermix and

**Table 1. General characteristics of the subjects used in the microarray data analysis**

| Variable                              | Healthy ( <i>n</i> = 21) | MetS ( <i>n</i> = 14) | Lean ( <i>n</i> = 14) | Obese ( <i>n</i> = 21) |
|---------------------------------------|--------------------------|-----------------------|-----------------------|------------------------|
| Age (years)                           | 37 ± 15                  | 49 ± 13               | 40 ± 15               | 43 ± 15                |
| Weight (kg)                           | 66 ± 11                  | 88 ± 13               | 61 ± 9                | 83 ± 9                 |
| BMI (kg m <sup>-2</sup> )             | 23 ± 3                   | 30 ± 4                | 21 ± 2                | 29 ± 3                 |
| Fat (%)                               | 30.3 ± 8.2               | 37.5 ± 7.4            | 25.2 ± 5.4            | 38.2 ± 5.4             |
| WC (cm)                               | 80 ± 9                   | 101 ± 10              | 77 ± 8                | 96 ± 10                |
| Systolic BP (mmHg)                    | 122 ± 10                 | 143 ± 7               | 123 ± 9               | 134 ± 9                |
| Diastolic BP (mmHg)                   | 73 ± 8                   | 86 ± 9                | 73 ± 9                | 96 ± 9                 |
| Triglycerides (mmol l <sup>-1</sup> ) | 1.40 ± 0.40              | 1.60 ± 0.38           | 1.40 ± 0.37           | 1.76 ± 0.41            |
| HDL (mmol l <sup>-1</sup> )           | 1.39 ± 0.38              | 0.97 ± 0.46           | 1.19 ± 0.41           | 1.01 ± 0.41            |

Data are given as mean ± SD. MetS, metabolic syndrome; BP, blood pressure; BMI, body mass index; WC, waist circumference; HDL, high density lipoprotein.

CFX96 Real-Time PCR Detection System (BioRad). Primer sequences and annealing temperatures were as follows: *PGC-1α* Fwd: 5'CACTTACAAGC CAAACCAACAACACT'3, Temp. 59°C; *PGC-1α* Rev.: 5'CAATAGTCTTGTCTCAAATGGGGA'3, Temp. 59°C; *GAPDH* Fwd: 5'CCACCCATGGCAAATTC'3, Temp. 60°C; *GAPDH* Rev.: 5'TGGGATTTCCATTGATGACAA'3, Temp. 60°C. Each sample was analysed in duplicate and the PCR cycle parameters were as follows: +95°C for 10 min, 40 cycles at +95°C for 10 s, at +59 or +60°C (*PGC-1α* and *GAPDH*, respectively) for 30 s and at +72°C for 30 s, followed by 5 s at +65°C. Relative expression levels for *FNDC5* and *PGC-1α* were calculated with the  $\Delta\Delta C_t$  method and normalized to the expression of *GAPDH*.

### Blood sample collection, ELISA and measurement of biochemical parameters

Blood samples were collected before and at 3 h post-exercise in the same way as for the abovementioned studies. Serum irisin levels were measured using a commercial enzyme immunoassay (EIA) kit (Irisin/FNDC-5 (16–127) (Human, Mouse, Rat), Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA) according to the manufacturer's instructions. The absorbance at 450 nm was measured using Wallac Victor3 1420 Multilabel Counter plate reader (Perkin Elmer, Waltham, MA, USA).

Plasma glucose, serum triglycerides, total cholesterol and high density lipoprotein (HDL) were analysed using the KONELAB 20XTi analyser (Thermo Fisher Scientific Inc., Waltham, MA, USA). Insulin was determined by immunofluorescence using the IMMULITE Analyser (Diagnostic Products Corp., Los Angeles, CA, USA). The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated as (Fasting insulin concentration × Fasting glucose concentration)/22.5.

## Results

### The effects of exercise on serum irisin and skeletal muscle *FNDC5* and *PGC-1α*

Quantitative PCR of skeletal muscle (vastus lateralis) biopsies and serum ELISA analysis show that in healthy, previously untrained men no significant changes are observed in skeletal muscle *PGC-1α*, *FNDC5* and serum irisin after 1 h low-intensity AE (middle-aged men *n* = 17), 21 week heavy-intensity EE training (middle-aged men *n* = 9) or 21 week heavy-intensity EE training combined with RE training (middle-aged men *n* = 9; Fig. 1). Large intra- and inter-individual variations in *PGC-1α*, *FNDC5* and serum irisin in response to EE and RE training were observed (Fig. 1A–C). Moreover, the changes in muscle *PGC-1α* mRNA expression or serum irisin were not consistently accompanied by corresponding changes in *FNDC5* (Figs 1D and E, and 2E and F).

To study whether the blood sampling time may have affected the results (acute blood sampling vs. 3 h post-exercise), we performed a heavy exercise bout (5 × 10 repetitions of bilateral knee extensions with a load of 10 RM) for 14 males with simultaneous blood sampling at 1, 15 and 30 min, and measured serum irisin. Compared to baseline levels no differences in serum irisin levels were found at any time point (Fig. 1H).

Of the different exercise regimens a single RE bout, however, significantly increased *PGC-1α* by 4-fold in young and by 2-fold in older men (young men *n* = 10, older men *n* = 11), while *FNDC5* mRNA increased by 1.4-fold (95% confidence interval (CI) 0.3–2.2) post-RE only in young men (Fig. 2).

### Irisin, *FNDC5*, glucose metabolism and health

We further determined whether the serum irisin levels were associated with selected blood parameters at baseline




in the subjects of aerobic exercise ( $n = 17$ ). Irisin was not associated with glucose, insulin or HOMA-IR (Table 2).

To assess whether *FNDC5* expression was associated with being overweight or metabolic disturbances, we analysed our existing microarray data comparing lean ( $n = 14$ ) and obese ( $n = 21$ ) subjects, as well as metabolically healthy subjects ( $n = 21$ ) with those classified to have metabolic syndrome ( $n = 14$ ) (Table 1). Despite the 741 and 1402 differentially expressed adipose tissue genes in obese subjects and subjects with metabolic syndrome, respectively (data not shown), no differences in *FNDC5* expression were found in adipose tissue or skeletal muscle.

## Discussion

After the initial excitement about the therapeutic implications of irisin following its discovery (Boström *et al.* 2012) several publications have questioned the expression of the irisin precursor *FNDC5* and the regulatory role of exercise therein. Contrary to the preliminary finding of Boström *et al.* (2012) an endurance exercise bout or longer-term endurance training alone or combined with resistance training did not increase *FNDC5* mRNA expression in skeletal muscle or irisin release in our study population. This was not due to a lack of response in muscle since RE, as expected, increased muscle strength,



**Figure 1**


Changes of *PGC-1α* (A), *FNDC5* mRNA expression (B) and serum irisin (C) in middle-aged, non-diabetic and previously untrained men after a 1 h low-intensity (50%  $\dot{V}_{O_{2max}}$ ) aerobic exercise (AE) performed with bicycle ergometry ( $n = 17$ ); 21 weeks endurance training (EE,  $n = 9$ ); combined endurance + resistance training (EE + RE,  $n = 9$ ), and in age-matched non-exercised controls (Con,  $n = 2$ ). In A, B and C the error bars represent mean values and the whiskers are 95% confidence intervals. The circles represent individual values. D, individual responses to exercise. Each line represents one individual and links the change of *PGC-1α* to the change of *FNDC5* mRNA after exercise. E, individual responses to exercise. Each line represents one individual and links the change of *FNDC5* mRNA to the change of serum irisin after exercise. (Data are pooled from panels A and B.) F, serum irisin concentrations ( $\text{ng ml}^{-1}$ ) before and after AE. G, serum irisin concentrations ( $\text{ng ml}^{-1}$ ) before and after EE and combined EE + RE. H, serum irisin concentrations after 1, 15 and 30 min of a heavy-exercise bout.

mTOR signalling and muscle fibre size (Hulmi *et al.* 2009b), EE training increased aerobic capacity (Ahtiainen *et al.* 2009; Karavirta *et al.* 2010) and the expression of exercise-responsive sirtuin 1 and cytochrome *c* proteins, and the phosphorylation of pyruvate dehydrogenase kinase 4 (Ahtiainen *et al.*, unpublished observations), and AE increased exercise-responsive AMP-activated protein kinase (AMPK) phosphorylation and sirtuin 1 expression (Pekkala *et al.*, unpublished observations).

Importantly, the changes in *PGC-1 $\alpha$*  mRNA expression were not consistently accompanied by corresponding changes in *FNDC5*, suggesting that factor(s) other than *PGC-1 $\alpha$*  may be involved in the regulation of *FNDC5* expression. Of note, *PGC-1 $\alpha$*  is one of the important regulators of energy metabolism (Rodgers *et al.* 2005, 2008). Therefore, various upstream mechanisms, including those that are exercise-inducible, may influence *PGC-1 $\alpha$*  and *FNDC5* mRNA expression. Accordingly, Timmons *et al.* (2012) detected no correlation between *PGC-1 $\alpha$*  and *FNDC5* and thus concluded that of the exercise-regulated genes probably the other approximately 1000 genes regulated by different types of exercise warrant more attention than just *FNDC5* alone when the beneficial

effects of exercise on health are under investigation (Timmons *et al.* 2012). In addition, surprisingly, in our study the changes in *FNDC5* expression were not consistently accompanied by changes in serum irisin suggesting that in addition to transcriptional regulation other processes may be involved in irisin release from the muscle.

The large intra- and inter-individual variation in *FNDC5* and irisin in response to different types of exercise indicates that exercise may not increase *FNDC5* mRNA in skeletal muscle or circulating irisin level in most people. According to our results and those of Timmons *et al.* (2012) it seems that the effects of exercise on serum irisin and skeletal muscle *FNDC5* are not consistent, and it is already clear from an increasing body of evidence that the beneficial effects of exercise on health also occur independently of irisin. In addition, sample collection time might influence the outcome. The sampling time and exercise protocol used by Boström *et al.* (2012) is not comprehensively described. They detected an increase in serum irisin after 8 weeks EE (Boström *et al.* 2012) whereas Huh *et al.* (2012) found an increase only after the first week and not long term (Huh *et al.* 2012). However,



**Figure 2**

Skeletal muscle mRNA fold changes of *PGC-1 $\alpha$*  and *FNDC5* after 1 h and 48 h of a single resistance exercise bout ( $5 \times 10$  RM leg press) in young (A,  $n = 10$ ) and older (B,  $n = 11$ ) men. In A and B the error bars represent mean values and the whiskers are 95% confidence intervals. The circles represent individual values. C–F, individual responses to exercise in young (C and D) and older (E and F) men. Each line represents one individual and links the change of *PGC-1 $\alpha$*  to the change of *FNDC5* mRNA.

**Table 2. Correlation of serum irisin levels with HOMA-IR, plasma glucose and serum insulin measured with oral glucose tolerance test (n = 17)**

| Parameter  | r (irisin) | P value |
|--|------------|---------|
| HOMA-IR  | 0.030      | 0.910   |
| Plasma glucose concentration (mmol l <sup>-1</sup> ) |            |         |
| 0 h  | -0.109     | 0.678   |
| 1 h  | -0.042     | 0.873   |
| 2 h  | -0.098     | 0.708   |
| Serum insulin (μIU ml <sup>-1</sup> )                |            |         |
| 0 h  | 0.076      | 0.773   |
| 1 h  | -0.051     | 0.846   |
| 2 h  | -0.112     | 0.667   |

we did not find differences in serum irisin levels using acute sampling times (1, 15 and 30 min after exercise). Thus, it remains unclear which kind of exercise protocol, intensity or duration, if any, would be optimal to increase circulating serum irisin levels in the general population.

The metabolic role of irisin, according to Boström *et al.* (2012), is characterized by increased energy expenditure and glucose homeostasis. Therefore it would be logical that irisin and *FNDC5* increase in response to aerobic or endurance exercise that are generally characterized by increased oxidative capacity and mitochondrial functions. However, we did not find an increase in irisin or *FNDC5* despite the increase in other metabolically or oxidatively important markers after exercise (see above). Resistance training alone with a large number of repetitions per muscle group (e.g. 10 repetitions used per set in the present study) can also lead to enhanced muscle endurance and muscle growth. We found increased *FNDC5* mRNA after RE together with *PGC-1α* suggesting that irisin may be associated with enhanced strength endurance due to this mode of resistance training with many repetitions per set. It is also possible that the anabolic effects (muscle growth) of RE are associated with increased *FNDC5* expression since Huh *et al.* (2012) also showed that irisin was mostly associated with muscle mass.

Irisin has been shown to improve glucose tolerance and insulin sensitivity in mice (Boström *et al.* 2012) and to correlate with glucose in humans (Huh *et al.* 2012). However, we did not find any correlation between serum irisin and glucose, insulin and HOMA-IR or glucose tolerance in middle-aged men. Moreover, related to its function in health and disease, unlike Moreno-Navarrete *et al.* (2013) we did not find decreased expression of *FNDC5* associated with obesity and metabolic syndrome either in adipose tissue or skeletal muscle. Our results suggest that the role of irisin and *FNDC5* in metabolic health may not be so straightforward and applicable to all clinical populations.

Finally, another important fact that might explain the inconsistent results is the serum irisin analysis technique itself. Boström *et al.* measured serum irisin using Western blot and quantified unglycosylated irisin instead of glycosylated irisin (Boström *et al.* 2012) even though many potential glycosylation sites of *FNDC5* are retained in the secreted irisin. A lack of glycosylation prevents proper protein folding and retention in endoplasmic reticulum (ER; Vagin *et al.* 2009; Roth *et al.* 2010). Nevertheless, mis-folded glycoproteins may still be secreted exhibiting altered functions (such as failure in receptor binding), a situation which is highly likely in ER stress commonly observed during exercise. While we used ELISA that detects the native conformation of irisin, Western blot of unglycosylated irisin probably reflects an unfolded polypeptide and therefore it is uncertain what proportion of the irisin measured in this way is functional.

In conclusion, our study suggests that in healthy, lean people: (1) exercise may not generally increase *FNDC5* expression in skeletal muscle, (2) factor(s) other than *PGC-1α* and transcriptional regulation may be involved in *FNDC5* expression and irisin release, and (3) the changes in serum irisin and skeletal muscle *FNDC5* in response to exercise are probably random, and there is little evidence to confirm any definitive link between exercise and *FNDC5* expression and irisin release in humans.

## References

- Ahtainen JP, Hulmi JJ, Kraemer WJ, Lehti M, Pakarinen A, Mero AA, Karavirta L, Sillanpää E, Selanne H, Alen M, Komulainen J, Kovanen V, Nyman K & Hakkinen K (2009). Strength [corrected], endurance or combined training elicit diverse skeletal muscle myosin heavy chain isoform proportion but unaltered androgen receptor concentration in older men. *Int J Sports Med* **30**, 879–887.
- Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP & Spiegelman BM (2012). A *PGC1-α*-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. *Nature* **481**, 463–468.
- Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE & Mantzoros CS (2012). *FNDC5* and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. *Metabolism* **61**, 1725–1738.
- Hulmi JJ, Kovanen V, Lisko I, Selanne H & Mero AA (2008). The effects of whey protein on myostatin and cell cycle-related gene expression responses to a single heavy resistance exercise bout in trained older men. *Eur J Appl Physiol* **102**, 205–213.
- Hulmi JJ, Kovanen V, Selanne H, Kraemer WJ, Häkkinen K & Mero AA (2009a). Acute and long-term effects of resistance exercise with or without protein ingestion on muscle hypertrophy and gene expression. *Amino Acids* **37**, 297–308.



- Hulmi JJ, Tannerstedt J, Selänne H, Kainulainen H, Kovanen V & Mero AA (2009b). Resistance exercise with whey protein ingestion affects mTOR signaling pathway and myostatin in men. *J Appl Physiol* **106**, 1720–1729.
- Karavirta L, Häkkinen A, Sillanpää E, García-López D, Kauhanen A, Haapasaari A, Alen M, Pakarinen A, Kraemer WJ, Izquierdo M, Gorostiaga E & Häkkinen K (2010). Effects of combined endurance and strength training on muscle strength, power and hypertrophy in 40–67-year-old men. *Scand J Med Sci Sports* **21**, 402–411.
- Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, Ricart W & Manuel-Fernández-Real J (2013). Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. *J Clin Endocrinol Metab* **98**, E769–778.
- Roberts MD, Bayless DS, Company JM, Jenkins NT, Padilla J, Childs TE, Martin JS, Dalbo VJ, Booth FW, Rector RS & Laughlin MH (2013). Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats. *Metabolism* **62**, 1052–1056.
- Roca-Rivada A, Castela C, Senin LL, Landrove MO, Baltar J, Crujeiras AB, Seoane LM, Casanueva FF & Pardo M (2013). FNDC5/irisin is not only a myokine but also an adipokine. *PLoS One* **8**, e60563.
- Rodgers JT, Lerin C, Gerhart-Hines Z & Puigserver P (2008). Metabolic adaptations through the PGC-1 $\alpha$  and SIRT1 pathways. *FEBS Lett* **582**, 46–53.
- Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM & Puigserver P (2005). Nutrient control of glucose homeostasis through a complex of PGC-1 $\alpha$  and SIRT1. *Nature* **434**, 113–118.
- Roth J, Zuber C, Park S, Jang I, Lee Y, Kysela KG, Le Fourn V, Santimaria R, Guhl B & Cho JW (2010). Protein N-glycosylation, protein folding, and protein quality control. *Mol Cells* **30**, 497–506.
- Sharma N, Castorena CM & Cartee GD (2012). Greater insulin sensitivity in calorie restricted rats occurs with unaltered circulating levels of several important myokines and cytokines. *Nutr Metab (Lond)* **9**, 90.
- Timmons JA, Baar K, Davidsen PK & Atherton PJ (2012). Is irisin a human exercise gene? *Nature* **488**, E9–10; discussion E10–11.
- Vagin O, Kraut JA & Sachs G (2009). Role of N-glycosylation in trafficking of apical membrane proteins in epithelia. *Am J Physiol Renal Physiol* **296**, F459–F469.

## Additional information

### Competing interests

None declared.

### Author contributions

All experiments were performed at the University of Jyväskylä in Finland except serum analysis, which was done at the University of Oulu in Finland. S.P., J.J.H., J.P.A., M.A., K.H. and S.C. designed the experiments. S.P., M.H. and K.A.M. performed the laboratory analyses and P.K.W. the statistical analyses. M.A. and K.N. were the study physicians. E.P., H.K., M.A., K.-H.H. and S.C. were involved in the interpretation of the results and revised the paper. S.P. wrote the paper. P.K.W., J.J.H., J.P.A., M.A., K.H. and S.C. revised the paper. All authors approved the final version of the manuscript.

### Funding

This work was financially supported by the Finnish Ministry of Education, The Central Finland Health Care District, Jyväskylä, Finland, Academy of Finland, Finnish Diabetes Research Foundation, and EVO (Northern Ostrobothnia Hospital District Research Grant).

### Acknowledgements

We thank Dr Omid Rasool, Dr Riitta Lahesmaa, Mrs Lingjia Kong and Dr Reija Autio for the processing of microarray samples and data. We also thank Mr Risto Puurtinen, Mrs Kaisa-Leena Tulla, Mrs Aila Ollikainen, Mrs Meeri Kröger and Mr Erkki Helkala for the excellent technical assistance.